Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Galit Alter

Showing results (361-370 of 535) with videos related to

Pageof 54
Sort By:
Nature Medicine|June 22, 2019
Publisher Correction: IFN-γ-independent immune markers of Mycobacterium tuberculosis exposureLenette L Lu, Malisa T Smith, Krystle K Q Yu, et al.
Journal of Virology|April 13, 2018
Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea PigsChristine A Bricault, James M Kovacs, Alexander Badamchi-Zadeh, et al.
Nature Communications|September 12, 2023
A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infectionAdam J Ronk, Nicole M Lloyd, Min Zhang, et al.
Nature|November 7, 2018
Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeysErica N Borducchi, Jinyan Liu, Joseph P Nkolola, et al.
Nature Medicine|May 22, 2019
IFN-γ-independent immune markers of Mycobacterium tuberculosis exposureLenette L Lu, Malisa T Smith, Krystle K Q Yu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 12, 2022
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIVEdgar T Overton, Isabelle R Weir, Markella V Zanni, et al.
Journal of Virology|March 30, 2005
The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine designMarcus Altfeld, Todd M Allen, Elizabeth T Kalife, et al.
Cell Reports|July 21, 2021
An intranasal vaccine durably protects against SARS-CoV-2 variants in miceAhmed O Hassan, Swathi Shrihari, Matthew J Gorman, et al.
Nature|October 5, 2018
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeysErica N Borducchi, Jinyan Liu, Joseph P Nkolola, et al.
Nature Medicine|September 5, 2018
Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIVMargaret E Ackerman, Jishnu Das, Srivamshi Pittala, et al.
Pageof 54

Showing results (361-370 of 535) with videos related to

Sort By:
Pageof 54
Nature Medicine|June 22, 2019
Publisher Correction: IFN-γ-independent immune markers of Mycobacterium tuberculosis exposureLenette L Lu, Malisa T Smith, Krystle K Q Yu, et al.
Journal of Virology|April 13, 2018
Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea PigsChristine A Bricault, James M Kovacs, Alexander Badamchi-Zadeh, et al.
Nature Communications|September 12, 2023
A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infectionAdam J Ronk, Nicole M Lloyd, Min Zhang, et al.
Nature|November 7, 2018
Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeysErica N Borducchi, Jinyan Liu, Joseph P Nkolola, et al.
Nature Medicine|May 22, 2019
IFN-γ-independent immune markers of Mycobacterium tuberculosis exposureLenette L Lu, Malisa T Smith, Krystle K Q Yu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 12, 2022
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIVEdgar T Overton, Isabelle R Weir, Markella V Zanni, et al.
Journal of Virology|March 30, 2005
The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine designMarcus Altfeld, Todd M Allen, Elizabeth T Kalife, et al.
Cell Reports|July 21, 2021
An intranasal vaccine durably protects against SARS-CoV-2 variants in miceAhmed O Hassan, Swathi Shrihari, Matthew J Gorman, et al.
Nature|October 5, 2018
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeysErica N Borducchi, Jinyan Liu, Joseph P Nkolola, et al.
Nature Medicine|September 5, 2018
Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIVMargaret E Ackerman, Jishnu Das, Srivamshi Pittala, et al.
Pageof 54